Core Insights - Creatd, Inc. announced that Catheter Precision, Inc. has acquired a 20% equity interest in its subsidiary Fly Flyte, Inc. through a secondary purchase from an existing shareholder, aligning with Creatd's strategy of nurturing technology-enabled subsidiaries while maintaining operational independence [1] - The CEO of Creatd emphasized the company's commitment to building a portfolio of small-cap operating companies, aiming to address market gaps created by the contraction of middle markets over the last two decades [2] - Fly Flyte is currently operational, providing AI-enabled regional aviation services that enhance accessibility and convenience, leveraging certified aircraft and established routes for real-time revenue generation [2] Strategic Developments - The partnership with NYSE-listed VTAK expands Fly Flyte's investor network, enhancing its growth potential [4] - Creatd is actively pursuing multiple acquisition discussions to advance its portfolio strategy [4] - Fly Flyte is positioned to transform regional aviation through its focus on accessibility, convenience, and technology-driven operations [4] Company Overview - Creatd, Inc. focuses on acquiring and growing technology-driven companies in sectors such as aviation, media, and advisory services, utilizing a shared services model to enhance efficiency and market reach [3]

Core Insights - Creatd, Inc. announced that Catheter Precision, Inc. has acquired a 20% equity interest in its subsidiary Fly Flyte, Inc. through a secondary purchase from an existing shareholder, aligning with Creatd's strategy of nurturing technology-enabled subsidiaries while maintaining operational independence [1] - The CEO of Creatd emphasized the company's commitment to building a portfolio of small-cap operating companies, aiming to address market gaps created by the contraction of middle markets over the last two decades [2] - Fly Flyte is currently operational, providing AI-enabled regional aviation services that enhance accessibility and convenience, leveraging certified aircraft and established routes for real-time revenue generation [2] Strategic Developments - The partnership with NYSE-listed VTAK expands Fly Flyte's investor network, enhancing its growth potential [4] - Creatd is actively pursuing multiple acquisition discussions to advance its portfolio strategy [4] - Fly Flyte is positioned to transform regional aviation through its focus on accessibility, convenience, and technology-driven operations [4] Company Overview - Creatd, Inc. focuses on acquiring and growing technology-driven companies in sectors such as aviation, media, and advisory services, utilizing a shared services model to enable efficient scaling and market reach [3]

Core Viewpoint - Catheter Precision, Inc. has signed a definitive agreement to acquire assets related to the Cardiac Pulmonary Nerve Stimulation (CPNS) System from Cardionomic, Inc. through its subsidiary Cardionomix, Inc. This acquisition aims to address acute decompensated heart failure (ADHF), a condition affecting over 1 million Americans annually, with promising initial clinical results indicating significant efficacy [1][2][4]. Group 1: Acquisition Details - The acquisition involves 1,000,000 shares of unregistered common stock and a three-year promissory note of $1.5 million at 4% interest, with no principal or interest due until maturity [5]. - The transaction is subject to normal closing conditions, including NYSE American listing approval [6]. Group 2: Clinical Efficacy - Initial clinical studies have shown significant positive results, including less worsening of acute heart failure, increased fluid loss without renal function deterioration, improved quality of life at thirty days, reduced mortality or hospitalization at six-month follow-up, and a 2.8x improvement over standard care in the WIN ratio [5]. Group 3: Market Potential - The U.S. market for the CPNS System is estimated to exceed $1 billion in annual revenues, given the high number of hospital admissions for heart failure [4]. - The therapy targets hospitalized ADHF patients with an ejection fraction of 50% or less, who exhibit fluid overload despite diuretic treatment [2]. Group 4: Strategic Partnerships - The acquisition is supported by previous investors, including the Cleveland Clinic Foundation, Abbott Laboratories, and New Enterprise Associates (NEA), who will receive economic interests in Catheter Precision's common stock and the Cardionomix note [4][9]. - Discussions are ongoing with various investors to secure additional funding for the new subsidiary, which will support the development of the acquired assets [4].

Core Points - Catheter Precision, Inc. announced that its audited financial statements for the year ended December 31, 2024, included an audit opinion with a Substantial Doubt Regarding Going Concern paragraph [1] - This announcement complies with NYSE American Company Guide Section 610(b), which mandates a separate public announcement for audit opinions containing a going concern paragraph [2] Financial Information - The audit opinion indicating substantial doubt about the company's ability to continue as a going concern was disclosed in the Annual Report on Form 10-K filed on March 31, 2025 [1] - The announcement does not alter the company's consolidated financial statements or its Annual Report on Form 10-K for the year ended December 31, 2024 [2]

Financial Highlights - Catheter Precision reported total assets of $27.7 million and total shareholders' equity of $11.8 million as of December 31, 2024 [3] - The company had 8,004,633 outstanding shares of common stock by the end of 2024 [3] - Fourth quarter revenue reached $149 thousand, marking a sequential increase of 55% over Q3 2024, while full year 2024 revenue totaled $420 thousand [3] - The net loss for the fourth quarter was $5.6 million, with $3.1 million attributed to non-cash charges; total net loss for 2024 was $16.6 million, including $7.5 million in non-cash charges [3] Operational Updates - A new Chief Commercial Officer joined in Q2 2024, leading to a significant overhaul of the sales team [3] - The first sales of the LockeT device occurred in Q2 2024, with sales growing sequentially each quarter [3] - By year-end 2024, 26 hospitals had evaluated the LockeT device through surgical procedures [3] - The company completed audits for LockeT's CE Mark in Q4 2024, with expectations to receive the CE Mark in Q2 2025, allowing sales in 32 European countries starting Q3 2025 [3] - VIVO marketing and sales efforts are ongoing in the US and several international markets, including Germany, Turkey, and the UK [3] Clinical Studies and Publications - Two clinical studies were published in 2024, focusing on non-invasive mapping systems and the combination of cardiac imaging with electrocardiographic information [3] - The first LockeT journal manuscript and two abstracts were published in 2024, detailing the feasibility, safety, and efficacy of the LockeT device [3] - Additional clinical studies for both VIVO and LockeT are ongoing or planned for 2025, including a Randomized Controlled Trial (RCT) for VIVO set to begin in Q3 2025 [3]

Financial Highlights - Total assets on December 31, 2024, were $27.7 million [3] - Total shareholders' equity on December 31, 2024, was $11.8 million [3] - Total outstanding shares of common stock on December 31, 2024, were 8,004,633 [3] - Fourth quarter revenue was $149 thousand, a sequential increase of 55% over Q3 2024 [3] - Full year 2024 revenue was $420 thousand [3] - Net loss for the fourth quarter was $5.6 million, with $3.1 million being non-cash charges [3] - Total net loss for 2024 was $16.6 million, with $7.5 million being non-cash charges [3] Operational Updates - A new Chief Commercial Officer (CCO) joined in Q2 2024, leading to a majority replacement of the prior sales team [2][3] - The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter [3] - By year-end, 26 institutions had evaluated LockeT through surgical procedures [3] - The CE Mark for LockeT is anticipated to be received in Q2 2025, allowing sales in 32 European countries [3] - Anticipated EU LockeT sales are expected to begin in Q3 2025 [3] - VIVO marketing and sales progress continues in the US and multiple international markets [3] Clinical Studies and Publications - Two clinical studies were published in 2024 related to VIVO and LockeT [3] - Multiple IRB approvals were received in Q4 2024 and Q1 2025 for new LockeT studies [3] - A Randomized Controlled Trial (RCT) for VIVO is planned to begin in Q3 2025 [3] Product Information - VIVO is a non-invasive 3D imaging system that streamlines workflow and reduces procedure time [5] - LockeT is a suture retention device intended to assist in hemostasis after percutaneous venous punctures [6]

S-1/A 1 rmed_s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on June 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) FORM S-1 Registration No. 333-279930 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 38-3661826 ( ...